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Abstract
Background: There are no definitive criteria for identifying which patients with The International Federation of
Gynecology and Obstetrics (FIGO) stage IB cervical cancer will benefit from adjuvant therapy after radical hysterectomy.
The aims of this study were to clarify the efficacy of adjuvant therapy and assess complications after radical
hysterectomy in patients with FIGO stage IB1 cervical cancer with intermediate risk factors.
Methods: Between January 2005 and December 2009, the medical records of 75 stage IB1 patients’ intermediate risk
factors (i.e., tumor size 2–4 cm, lymphovascular involvement, and/or deep stromal invasion >1/2) who underwent radical
hysterectomy at six institutions were collected, and these patients were enrolled in this nonrandomized retrospective
study. We simplified the criteria of intermediate risk factors as much as possible, as the criteria adopted in some clinical
studies are complicated in practice.
Results: The patients were grouped according to the receipt of adjuvant therapy as follows: 46 patients, no further
treatment; 19 patients, external beam radiation treatment, including 9 patients who received brachytherapy; 5 patients,
concurrent chemoradiotherapy (CCRT); and 5 patients, chemotherapy (CT). The clinical outcomes and complications in
each group were analyzed. After an average follow-up of 82.6 months (range, 24–135 months), only one patient with all
three risk factors who received radiotherapy (RT) experienced recurrence. Excluding this patient, the remaining patients
who received RT, CCRT, or CT had two or three risk factors. Lymphedema was significantly more common among
patients who received RT or CCRT, whereas the incidence of ileus and ureteral obstruction was not different among the
treatment groups. However, an unsutured peritoneum increased the risk of ileus.
Conclusions: The findings of this study suggest that RT and CCRT after radical hysterectomy are not beneficial in
patients with intermediate risk factors. In particular, RT and CCRT appeared to increase the incidence of lymphedema.
A prospective randomized study is needed to verify the findings of this study.
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Background
Cervical cancer is the fourth most common cancer among
women worldwide and the second most diagnosed cancer
in developing countries [1]. Radical hysterectomy with pelvic
lymphadenectomy has been a primary treatment in women
with stage IB cervical cancer, and the procedure is associated
with a 5-year survival rate of 87–92 % [2]. Radiotherapy
(RT) is a feasible technique that provides similar outcomes
as radical hysterectomy [2–4]. Surgery enables pathological
examination by surgeons, permitting identification of risk
factors for cancer recurrence. In general, patients with para-
metrial invasion, a positive vaginal margin, or positive pelvic
lymph nodes who are diagnosed as being at high risk are
assigned to receive adjuvant therapies. By contrast, large
tumor size, deep stromal invasion, and lymphovascular inva-
sion are classified as intermediate risk factors, and adjuvant
therapy for patients with these risk factors remains contro-
versial. Although the criteria for intermediate risk factors
defined by the Gynecologic Oncology Group (GOG) study
[5] have been widely accepted, each institution offers adju-
vant therapy to patients based on its own protocol. Thus,
there is always a problem of interpreting discrepant results
between studies because of the different study models. On
the contrary, it has been recognized that postoperative RT
results in a significant increase in the incidence of adverse
events affecting quality of life, such as lymphedema, ileus,
and ureteral obstruction [6–8].
The GOG study concluded that pelvic RT after rad-
ical hysterectomy significantly improves progression-
free survival and benefits patients with histological types
of adenocarcinoma and adenosquamous carcinoma [9].
The aims of the current retrospective study were to evalu-
ate the effect of RT and treatment-related morbidity after
radical hysterectomy for patients with intermediate risk as
defined by simplified criteria.
Methods
Between 2005 and 2009, the medical records of 89 stage
IB1 patients with intermediate risk factors (i.e., tumor size
2–4 cm, lymphovascular involvement, and/or deep stromal
invasion >1/2) who underwent type III radical hysterectomy
as defined by Piver et al. [10] and bilateral pelvic lymphade-
nectomy were obtained for this retrospective study from six
institutions belonging to the Gynecologic Oncology Trial
and Investigation Consortium of North Kanto (GOTIC):
Gunma University, Tsukuba University, Jichi Medical Uni-
versity, National Defense Medical College, Saitama Medical
University International Medical Center, and Tochigi Pre-
fectural Cancer Center. None of the patients had received
preoperative treatment such as neoadjuvant chemotherapy
(CT) or RT. Informed consent was not obtained from each
participant because this was a retrospective study. Instead
of that, all participants were given the right to withdraw the
use of the data. The protocol of this study was approved
based on the necessity of the individual institutions’ ethical
committees.
Based on each institution’s criteria, patients received
adjuvant therapy, including RT, CT, or concurrent che-
moradiotherapy (CCRT). RT consisted of conventional
external beam (EBRT) to the pelvis (28–42 Gy) in frac-
tions of 1.8–2.0 Gy for 28–42 days. Nine patients in the
RT group also received vaginal brachytherapy (BRA) in
fractions of 4–7 Gy for a total dose of 7–21 Gy. In the
CCRT group, cisplatin (40 mg/m2) was infused intra-
venously every week. In the CT group, patients received
paclitaxel (175 mg/m2) plus carboplatin (AUC 6) every
3 weeks for 6 cycles.
Data regarding tumor size (MS), histopathological find-
ings, depth of stromal invasion [11], and lymphovascular
space invasion (LVSI) are summarized in Table 1. All pa-
tients received regular follow-up. During follow-up, compli-
cations such as ileus and ureteral obstruction were classified
according to the Common Toxicity Criteria. The severity of
lymphedema was rated according to the staging system of
the International Society of Lymphology as follows: stage 0,
a latent or sub-clinical condition in which swelling in not
evident; stage 1, temporary visible swelling that can be
reduced by elevation of the limb; stage 2, clear pitting and
limb elevation cannot reduce tissue swelling; and stage 3,
also known as lymphostatic elephantiasis, tissue becomes
extremely swollen, leading to skin changes such as acantho-
sis, fat deposits, and warty overgrowths [12].
Statistically significant differences in the severity of ad-
verse events, namely lymphedema, ileus, and ureteral ob-
struction, as a result of no further treatment (NFT, n = 46),
RT and CCRT (n = 24), or CT (n = 5) were analyzed using
the Kruskal-Wallis or chi-squared test. All tests were
two-tailed, and a P value <0.05 was considered statisti-
cally significant.
The presence or absence of complications was deter-
mined, and cross-tabulation was performed when the retro-
peritoneum was opened or closed during surgery and when
RT was or was not administered. In addition, odds ratios
and 95 % confidence intervals for the presence or absence
of complications were calculated using logistic regression
analyses based on whether the retroperitoneum was opened
or whether RT was performed.
JMP ver. 9 (SAS Institution Japan Inc., Tokyo, Japan)
was used for all analyses.
Results
Eighty-nine patients were enrolled in this retrospective study
from six institutions; meanwhile, 14 patients were excluded
because of incompatibility with the inclusion criteria and in-
complete follow-up data. Overall, the study included 51, 20,
and 4 patients with squamous cell carcinoma, adenocarcin-
oma, and adenosquamous histology, respectively (Table 1).
One patient with all three intermediate risk factors who
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received EBRT and BRA died of a recurrent tumor in the
lungs 24 months later. All other patients are alive without
recurrence, and they have been followed up for an average
of 84.3 months (range, 47–135 months).
Table 2 shows the characteristics of intermediate risk
factors in this group of patients. Among the 75 patients,
24 received either RT or CCRT and 5 were treated with
CT alone. Only a single patient who had one intermediate
risk factor received EBRT and BRA. By contrast, 19/24
(79.2 %) patients who had all three intermediate risk fac-
tors as defined in this study received adjuvant therapy.
Lymphedema was observed more frequently in patients
who received postoperative RT than in those who did not
receive RT or CT (P < 0.001). The risks of ileus and ureteral
obstruction were not significantly different between patients
who received NFT/CT or RT/CCRT. Other radiation-
related adverse effects such as cystitis and proctitis were
extremely rare (Table 3). We further assessed the severity of
lymphedema associated with RT, finding that more
patients who receive RT developed grade 2 or 3 lymph-
edema (P < 0.001) (Table 4).
Retroperitoneal suturing after lymphadenectomy was
also assessed to evaluate the prophylactic effect of an
unsutured pelvic peritoneum on lymphedema risk. The
overall lymphedema rate was comparable between pa-
tients with an unsutured pelvic peritoneum and those
Table 2 Pathological characteristics of intermediate risk cervical
cancer
Risk factor Adjuvant therapy
NFT RT/CCRT CT
n = 46 n = 24 n = 5
MS 18 1 0
SI 4 0 0
LVSI 1 0 0
MS + SI 12 4 1
MS + LVSI 5 4 0
SI + LVSI 1 0 0
MS + SI + LVSI 5 15 4
Abbreviations: NFT no further treatment, RT radiation therapy, CCRT concurrent
chemoradiotherapy, CT chemotherapy, MS mass size (2 ≤ tumor < 4 cm), SI
stromal invasion, LVSI lymphovascular space involvement
Table 1 Patient characteristics (n = 75)
RT/CCRT
NFT EBRT EBRT + BRA EBRT (CCRT) EBRT + BRA (CCRT) CT
n = 46 n = 10 n = 9 n = 2 n = 3 n = 5
Age (years) 46.8 (27–78) 44.7 (27–67) 49.9 (31–69) 63.5 (55–72) 38.0 (33–43) 53.0 (34–66)
Follow-up time (months) 78.7 (51–118) 90.6 (64–117) 77.8 (24–120) 98.0 (61–135) 113.3 (110–117) 86.8 (61–134)
Tumor size
<2 cm 6 (13.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
2 cm≤ tumor < 4 cm 40 (87.0 %) 10 (100.0 %) 9 (100.0 %) 2 (100.0 %) 3 (100.0 %) 5 (100.0 %)
Histologic type
Squamous 31 (67.4 %) 10 (100.0 %) 9 (100.0 %) 1 (50.0 %) 0 (0.0 %) 0 (0.0 %)
Adenocarcinoma 12 (26.1 %) 0 (0.0 %) 0 (0.0 %) 1 (50.0 %) 2 (66.7 %) 5 (100.0 %)
Adenosquamous 3 (6.5 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 1 (33.3 %) 0 (0.0 %)
Stromal invasion
<1/2 24 (52.2 %) 3 (30.0 %) 2 (22.2 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
≥1/2 22 (47.8 %) 7 (70.0 %) 7 (77.8 %) 2 (100.0 %) 3 (100.0 %) 5 (100.0 %)
Lymphovascular invasion
– 37 (80.4 %) 1 (10.0 %) 3 (33.3 %) 0 (0.0 %) 1 (33.3 %) 1 (20.0 %)
+ 9 (19.6 %) 9 (90.0 %) 6 (66.7 %) 2 (100.0 %) 2 (66.7 %) 4 (80.0 %)
Abbreviations: NFT no further treatment, RT radiation therapy, CCRT concurrent chemoradiotherapy, EBRT external beam radiation therapy, BRA brachytherapy,
CT chemotherapy
Table 3 The frequency of complications by treatment regimens
Treatment P valuea
NFT (n = 46) RT/CCRT (n = 24) CT (n = 5)
Lymphedema 8 14 0 0.001
Ileus 9 4 0 0.544
Ureter obstruction 1 2 1 0.184
Radiation cystitis 0 –
Radiation proctitis 2 –
Lymphedema level is rated according to the staging system by the
International Society of Lymphology
Abbreviations: NFT no further treatment, CT chemotherapy, RT
radiation therapy
aChi-squared test
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with a sutured pelvic peritoneum (Table 5). However, an
unsutured pelvic peritoneum was significantly associated
with ileus among patients who did not receive adjuvant
RT (Fig. 1).
Discussion
The outcome of surgery with or without adjuvant RT in
patients with early-stage cervical cancer has been de-
bated by many researchers. In general, RT has been
demonstrated to significantly decrease the risk of local
recurrence. However, overall survival is not conclu-
sively improved, whereas certain subset analyses illus-
trated a positive effect of RT on the reduction of
recurrence, for example, the GOG 92 study suggested
that RT is effective for patients with a combination of
deep stromal invasion and large tumor size (≥4 cm) [9].
Tumor size ≥4 cm has been strongly correlated with
recurrence [13–17]. As we assumed that tumor size
≥4 cm was a high risk factor even in the intermediate
risk group, we excluded patients with tumor diameters
≥4 cm in this study. It is also accepted that stromal
invasion by tumors is an important prognostic factor,
and a majority of studies evaluated invasion depth via
measurements in absolute millimeters or fractions of
muscle layer [9, 17]. Stromal invasion in fractional sec-
onds was used in this study because variable thickness
in the cervical wall might not reflect the extent of stro-
mal invasion. In addition, measurement in fractional
thirds appeared difficult, especially in patients with a
thin cervical wall, and it might increase discrepancies
because of the multi-institutional nature of the study.
Previously, a combination of intermediate risk factors,
such as large tumor size, LVSI, and stromal invasion,
was associated with incremental recurrence rates of up
to 15–20 % [5, 13, 16, 17]. In this study, only one pa-
tient (1/24) with a single risk factor received adjuvant
RT, whereas 28/51 patients with multiple risk factors
received adjuvant therapy (Table 2). However, this study
has some limitations, including its retrospective nature
and the possible diversity of treatment modalities
among institutions, resulting in heterogeneity among
the treatment groups. For example, the introduction of
CCRT for treating high risk cervical cancer probably
influenced some institutions to utilize CCRT, as 4/5
patients who received CCRT had all three risk factors
(Table 1), which may result in bias in interpreting the
results. In this study, only one patient with all three
intermediate risk factors who received RT and BRA
died of recurrent tumor in the lungs 24 months later.
This finding suggests that adjuvant RT does not benefit
patients with intermediate risk factors as defined in this
study. These issues can be addressed via a randomized
design study in the future.
Another purpose of this study was to assess adverse
events associated with RT, as adjuvant RT has long been
known to increase complications [18, 19]. Adjuvant CT
alone for post-radical hysterectomy patients has been
revealed to provide a better postoperative quality of life by
eliminating RT-related morbidities such as small-bowel
obstruction or leg edema [6, 8], as also supported by our
results (Table 3). Based on the small number of cases of
ileus and ureteral obstruction, there was no difference
between NFT/CT and RT/CCRT, which was consistent
with a meta-analysis [11] of two combined trials by Bilek
et al. [20] and GOG 92 [9]. Conversely, the incidence of
lymphedema was significantly higher and the adverse event
was of greater severity for patients who received RT or
CCRT (P < 0.001). Several studies indicated that an unsu-
tured peritoneum after pelvic lymphadenectomy reduced
the risk of lymphocyst formation [21, 22]. In this study, we
assessed whether the incidence of lymphedema improved
when the retroperitoneum was left open. In contrast to a
previous report suggesting that an unsutured peritoneum
significantly reduced the risk of lymphedema [23], this
strategy did not provide a significant advantage in avoiding
lymphedema in this study (Table 5). Lymphedema is most
commonly diagnosed within the first year, but a certain
number of patients manifest symptoms in later years [24,
Table 5 Adverse events in unsutured and sutured peritoneum
status
Not sutured (n = 36) Sutured (n = 39)
Radiation (−)
Ileus (−) 21 22
Ileus (+) 9 0
Lymphedema (−) 24 19
Lymphedema (+) 6 3
Radiation (+)
Ileus (−) 5 14
Ileus (+) 1 3
Lymphedema (−) 3 7
Lymphedema (+) 3 10
Table 4 Incidences of lymphedema grades by treatment regimens
Treatment P valuea
NFT (n = 46) RT/CCRT (n = 24) CT (n = 5)
Lymphedema 0.001
Grade 0 38 10 5
Grade 1 7 7 0
Grade 2 1 6 0
Grade 3 0 1 0
Lymphedema level is rated according to the staging system by the
International Society of Lymphology
Abbreviations: NFT no further treatment, CT chemotherapy, RT
radiation therapy
aKruskal-Wallis test
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25]. Thus, the possible reason for discrepant results be-
tween studies may be attributable to the follow-up dur-
ation; specifically, the average observation period was
82.6 months in our study, whereas other studies evaluated
patients for 3 years after surgery. Intriguingly, our study
demonstrated that an unsutured peritoneum without RT
significantly increased the incidence of ileus, whereas
there was no difference between an unsutured and su-
tured peritoneum regarding the risks of lymphedema and
ureteral obstruction (Fig. 1).
Conclusions
In the present study, postoperative adjuvant RT significantly
increased adverse events for intermediate risk patients as
defined in this study. To date, no trial has established a
solid consensus regarding RT after surgery for early-stage
cervical cancer. Although this retrospective study included
a limited number of patients, the results provide useful in-
formation for further consideration in the management of
patients with intermediate risk cervical cancer.
Abbreviations
BRA, brachytherapy; EBRT, external beam radiation therapy; CCRT, concurrent
chemoradiotherapy; CT, chemotherapy; LVSI, lymphovascular space invasion;
MS, tumor size; NFT, no further treatment; RT, radiation treatment; SI, stromal
invasion
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Fig. 1 Adverse events for patients with an unsutured pelvic peritoneum who did not receive radiotherapy. Horizontal lines represent odds ratio
(diamonds) with 95 % confidence intervals (CIs)
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